Logo image of 6IV.DE

INVENTIVA SA (6IV.DE) Stock Fundamental Analysis

Europe - Frankfurt Stock Exchange - FRA:6IV - FR0013233012 - Common Stock

4.37 EUR
+0.43 (+10.77%)
Last: 1/12/2026, 7:00:00 PM
Fundamental Rating

2

We assign a fundamental rating of 2 out of 10 to 6IV. 6IV was compared to 83 industry peers in the Biotechnology industry. Both the profitability and financial health of 6IV have multiple concerns. While showing a medium growth rate, 6IV is valued expensive at the moment.


Dividend Valuation Growth Profitability Health

Quickly go to:

0

1. Profitability

1.1 Basic Checks

6IV had negative earnings in the past year.
In the past year 6IV has reported a negative cash flow from operations.
6IV had negative earnings in each of the past 5 years.
6IV had a negative operating cash flow in each of the past 5 years.
6IV.DE Yearly Net Income VS EBIT VS OCF VS FCF6IV.DE Yearly Net Income VS EBIT VS OCF VS FCFYearly Net Income VS EBIT VS OCF VS FCF 2016 2017 2018 2019 2020 2021 2022 2023 2024 -50M -100M -150M

1.2 Ratios

6IV's Return On Assets of -173.72% is on the low side compared to the rest of the industry. 6IV is outperformed by 83.13% of its industry peers.
Industry RankSector Rank
ROA -173.72%
ROE N/A
ROIC N/A
ROA(3y)-120.12%
ROA(5y)-85.05%
ROE(3y)N/A
ROE(5y)N/A
ROIC(3y)N/A
ROIC(5y)N/A
6IV.DE Yearly ROA, ROE, ROIC6IV.DE Yearly ROA, ROE, ROICYearly ROA, ROE, ROIC 2016 2017 2018 2019 2020 2021 2022 2023 2024 0 1K 2K 3K

1.3 Margins

The Profit Margin and Operating Margin and Gross Margin are not available for 6IV so they could not be analyzed.
Industry RankSector Rank
OM N/A
PM (TTM) N/A
GM N/A
OM growth 3YN/A
OM growth 5YN/A
PM growth 3YN/A
PM growth 5YN/A
GM growth 3YN/A
GM growth 5YN/A
6IV.DE Yearly Profit, Operating, Gross Margins6IV.DE Yearly Profit, Operating, Gross MarginsYearly Profit, Operating, Gross Margins 2016 2017 2018 2019 2020 2021 2022 2023 2024 -2K -4K -6K -8K

More info and screens

3

2. Health

2.1 Basic Checks

6IV does not have a ROIC to compare to the WACC, probably because it is not profitable.
6IV has more shares outstanding than it did 1 year ago.
Compared to 5 years ago, 6IV has more shares outstanding
6IV has a better debt/assets ratio than last year.
6IV.DE Yearly Shares Outstanding6IV.DE Yearly Shares OutstandingYearly Shares Outstanding 2016 2017 2018 2019 2020 2021 2022 2023 2024 20M 40M 60M 80M
6IV.DE Yearly Total Debt VS Total Assets6IV.DE Yearly Total Debt VS Total AssetsYearly Total Debt VS Total Assets 2016 2017 2018 2019 2020 2021 2022 2023 2024 20M 40M 60M 80M 100M

2.2 Solvency

Based on the Altman-Z score of -1.33, we must say that 6IV is in the distress zone and has some risk of bankruptcy.
6IV's Altman-Z score of -1.33 is on the low side compared to the rest of the industry. 6IV is outperformed by 62.65% of its industry peers.
Industry RankSector Rank
Debt/Equity N/A
Debt/FCF N/A
Altman-Z -1.33
ROIC/WACCN/A
WACC7.84%
6IV.DE Yearly LT Debt VS Equity VS FCF6IV.DE Yearly LT Debt VS Equity VS FCFYearly LT Debt VS Equity VS FCF 2016 2017 2018 2019 2020 2021 2022 2023 2024 0 50M -50M 100M -100M

2.3 Liquidity

A Current Ratio of 2.96 indicates that 6IV has no problem at all paying its short term obligations.
With a decent Current ratio value of 2.96, 6IV is doing good in the industry, outperforming 61.45% of the companies in the same industry.
6IV has a Quick Ratio of 2.96. This indicates that 6IV is financially healthy and has no problem in meeting its short term obligations.
6IV's Quick ratio of 2.96 is fine compared to the rest of the industry. 6IV outperforms 66.27% of its industry peers.
Industry RankSector Rank
Current Ratio 2.96
Quick Ratio 2.96
6IV.DE Yearly Current Assets VS Current Liabilites6IV.DE Yearly Current Assets VS Current LiabilitesYearly Current Assets VS Current Liabilites 2016 2017 2018 2019 2020 2021 2022 2023 2024 20M 40M 60M 80M 100M

More info and screens

4

3. Growth

3.1 Past

The earnings per share for 6IV have decreased strongly by -74.11% in the last year.
The Revenue for 6IV has decreased by -12.84% in the past year. This is quite bad
Measured over the past years, 6IV shows a small growth in Revenue. The Revenue has been growing by 5.62% on average per year.
EPS 1Y (TTM)-74.11%
EPS 3YN/A
EPS 5YN/A
EPS Q2Q%-71.33%
Revenue 1Y (TTM)-12.84%
Revenue growth 3Y29.92%
Revenue growth 5Y5.62%
Sales Q2Q%10763.41%

3.2 Future

6IV is expected to show quite a strong growth in Earnings Per Share. In the coming years, the EPS will grow by 15.92% yearly.
6IV is expected to show a strong growth in Revenue. In the coming years, the Revenue will grow by 123.15% yearly.
EPS Next Y44.75%
EPS Next 2Y24.76%
EPS Next 3Y14.52%
EPS Next 5Y15.92%
Revenue Next Year1.86%
Revenue Next 2Y-43.78%
Revenue Next 3Y54.3%
Revenue Next 5Y123.15%

3.3 Evolution

When comparing the Revenue growth rate of the last years to the growth rate of the upcoming years, we see that the growth is accelerating.
6IV.DE Yearly Revenue VS Estimates6IV.DE Yearly Revenue VS EstimatesYearly Revenue VS Estimates 2015 2017 2019 2021 2023 2025 2027 2029 2031 2033 500M 1B 1.5B
6IV.DE Yearly EPS VS Estimates6IV.DE Yearly EPS VS EstimatesYearly EPS VS Estimates 2017 2018 2019 2020 2021 2022 2023 2024 2025 2026 2027 2028 2029 2030 2031 0 2 -2 4 6

More info and screens

0

4. Valuation

4.1 Price/Earnings Ratio

The Price/Earnings Ratio is negative for 6IV. In the last year negative earnings were reported.
Also next year 6IV is expected to report negative earnings again, which makes the also the Forward Price/Earnings Ratio negative.
Industry RankSector Rank
PE N/A
Fwd PE N/A
6IV.DE Price Earnings VS Forward Price Earnings6IV.DE Price Earnings VS Forward Price Earnings ChartPrice Earnings - Forward Price Earnings PE FPE 0 20 40 60

4.2 Price Multiples

Industry RankSector Rank
P/FCF N/A
EV/EBITDA N/A
6IV.DE Per share data6IV.DE EPS, Sales, OCF, FCF, BookValue per sharePer Share Data Per Share 0 -1 -2 -3

4.3 Compensation for Growth

A more expensive valuation may be justified as 6IV's earnings are expected to grow with 14.52% in the coming years.
PEG (NY)N/A
PEG (5Y)N/A
EPS Next 2Y24.76%
EPS Next 3Y14.52%

More info and screens

0

5. Dividend

5.1 Amount

No dividends for 6IV!.
Industry RankSector Rank
Dividend Yield 0%

More info and screens

INVENTIVA SA

FRA:6IV (1/12/2026, 7:00:00 PM)

4.37

+0.43 (+10.77%)

Chartmill FA Rating
GICS SectorHealth Care
GICS IndustryGroupPharmaceuticals, Biotechnology & Life Sciences
GICS IndustryBiotechnology
Earnings (Last)11-21 2025-11-21
Earnings (Next)02-16 2026-02-16/amc
Inst Owners43.32%
Inst Owner ChangeN/A
Ins Owners4.97%
Ins Owner ChangeN/A
Market Cap834.75M
Revenue(TTM)13.61M
Net Income(TTM)-310.88M
Analysts87.14
Price Target12.16 (178.26%)
Short Float %N/A
Short RatioN/A
Dividend
Industry RankSector Rank
Dividend Yield 0%
Yearly DividendN/A
Dividend Growth(5Y)N/A
DPN/A
Div Incr YearsN/A
Div Non Decr YearsN/A
Ex-DateN/A
Surprises & Revisions
EPS beat(2)N/A
Avg EPS beat(2)N/A
Min EPS beat(2)N/A
Max EPS beat(2)N/A
EPS beat(4)N/A
Avg EPS beat(4)N/A
Min EPS beat(4)N/A
Max EPS beat(4)N/A
EPS beat(8)N/A
Avg EPS beat(8)N/A
EPS beat(12)N/A
Avg EPS beat(12)N/A
EPS beat(16)N/A
Avg EPS beat(16)N/A
Revenue beat(2)N/A
Avg Revenue beat(2)N/A
Min Revenue beat(2)N/A
Max Revenue beat(2)N/A
Revenue beat(4)N/A
Avg Revenue beat(4)N/A
Min Revenue beat(4)N/A
Max Revenue beat(4)N/A
Revenue beat(8)N/A
Avg Revenue beat(8)N/A
Revenue beat(12)N/A
Avg Revenue beat(12)N/A
Revenue beat(16)N/A
Avg Revenue beat(16)N/A
PT rev (1m)0%
PT rev (3m)N/A
EPS NQ rev (1m)0%
EPS NQ rev (3m)N/A
EPS NY rev (1m)1.72%
EPS NY rev (3m)N/A
Revenue NQ rev (1m)0%
Revenue NQ rev (3m)N/A
Revenue NY rev (1m)19.96%
Revenue NY rev (3m)N/A
Valuation
Industry RankSector Rank
PE N/A
Fwd PE N/A
P/S 61.33
P/FCF N/A
P/OCF N/A
P/B N/A
P/tB N/A
EV/EBITDA N/A
EPS(TTM)-3.62
EYN/A
EPS(NY)-0.99
Fwd EYN/A
FCF(TTM)-0.48
FCFYN/A
OCF(TTM)-0.48
OCFYN/A
SpS0.07
BVpS-0.05
TBVpS-0.05
PEG (NY)N/A
PEG (5Y)N/A
Graham NumberN/A
Profitability
Industry RankSector Rank
ROA -173.72%
ROE N/A
ROCE N/A
ROIC N/A
ROICexc N/A
ROICexgc N/A
OM N/A
PM (TTM) N/A
GM N/A
FCFM N/A
ROA(3y)-120.12%
ROA(5y)-85.05%
ROE(3y)N/A
ROE(5y)N/A
ROIC(3y)N/A
ROIC(5y)N/A
ROICexc(3y)N/A
ROICexc(5y)N/A
ROICexgc(3y)N/A
ROICexgc(5y)N/A
ROCE(3y)N/A
ROCE(5y)N/A
ROICexgc growth 3YN/A
ROICexgc growth 5YN/A
ROICexc growth 3YN/A
ROICexc growth 5YN/A
OM growth 3YN/A
OM growth 5YN/A
PM growth 3YN/A
PM growth 5YN/A
GM growth 3YN/A
GM growth 5YN/A
F-Score4
Asset Turnover0.08
Health
Industry RankSector Rank
Debt/Equity N/A
Debt/FCF N/A
Debt/EBITDA N/A
Cap/Depr 1.71%
Cap/Sales 0.93%
Interest Coverage N/A
Cash Conversion N/A
Profit Quality N/A
Current Ratio 2.96
Quick Ratio 2.96
Altman-Z -1.33
F-Score4
WACC7.84%
ROIC/WACCN/A
Cap/Depr(3y)20.07%
Cap/Depr(5y)N/A
Cap/Sales(3y)3.77%
Cap/Sales(5y)20.51%
Profit Quality(3y)N/A
Profit Quality(5y)N/A
High Growth Momentum
Growth
EPS 1Y (TTM)-74.11%
EPS 3YN/A
EPS 5YN/A
EPS Q2Q%-71.33%
EPS Next Y44.75%
EPS Next 2Y24.76%
EPS Next 3Y14.52%
EPS Next 5Y15.92%
Revenue 1Y (TTM)-12.84%
Revenue growth 3Y29.92%
Revenue growth 5Y5.62%
Sales Q2Q%10763.41%
Revenue Next Year1.86%
Revenue Next 2Y-43.78%
Revenue Next 3Y54.3%
Revenue Next 5Y123.15%
EBIT growth 1Y2.1%
EBIT growth 3YN/A
EBIT growth 5YN/A
EBIT Next Year8.14%
EBIT Next 3Y3.93%
EBIT Next 5Y22.65%
FCF growth 1Y-42.56%
FCF growth 3YN/A
FCF growth 5YN/A
OCF growth 1Y-43.45%
OCF growth 3YN/A
OCF growth 5YN/A

INVENTIVA SA / 6IV.DE FAQ

Can you provide the ChartMill fundamental rating for INVENTIVA SA?

ChartMill assigns a fundamental rating of 2 / 10 to 6IV.DE.


What is the valuation status of INVENTIVA SA (6IV.DE) stock?

ChartMill assigns a valuation rating of 0 / 10 to INVENTIVA SA (6IV.DE). This can be considered as Overvalued.


What is the profitability of 6IV stock?

INVENTIVA SA (6IV.DE) has a profitability rating of 0 / 10.


How financially healthy is INVENTIVA SA?

The financial health rating of INVENTIVA SA (6IV.DE) is 3 / 10.